Outlined so well with costs etc. by this gentleman neufstrong.com/neuronata-r

Given Canada’s NOC/c pathway for potential early approval, we could see similar stuff here, with the added concern of whether it damages Cdn trial sites being chosen bc companies would have to allow standard of care treatment, which would complicate their studies.

Agreed. And I also hate to see people with ALS waiting with high hopes for any trial because they have been helped to believe it has better evidence of efficacy than it does.

Agreed. I just read it & this will be a great tool for advocates of good science to reference. It covers so many key things that we all talk about in a very brief & clear manner. Thank you @rpavaneijk.bsky.social!

You must be having a fun year!

Eventually some may say it is the renowned Verb Hotel, which is fun.

Thank you. Can't wait to read this. Given the authors & the current P2 --> P3 landscape, I can only imagine this will be an important & timely piece.

My concern with enrolling fast progressors is based on the learnings from tofersen. If we effectively hit the primary upstream target of pathogenesis & it's still not early enough to stop disease, how can we expect to have a measurable effect by targeting one of many generic, downstream mechanisms?

You’re getting to be almost as good as Ahmad at selfies.